Evidence map›Paper›PMID 34754024›Full record

ArticleScientific reports2021

Association between MR-proADM concentration and treatment intensity of antihypertensive agents in chronic kidney disease patients with insufficient blood pressure control.

Motoshi Iwao, Ryota Tanaka, Yosuke Suzuki, Takeshi Nakata, Kohei Aoki, Akihiro Fukuda, Naoya Fukunaga, Ryosuke Tatsuta, Keiko Ohno, Hirotaka Shibata and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Motoshi IwaoDepartment of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan.
Ryota TanakaDepartment of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan. rtanaka@oita-u.ac.jp.
Yosuke SuzukiDepartment of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Noshio, Tokyo, Japan.
Takeshi NakataDepartment of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan.
Kohei AokiDepartment of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan.
Akihiro FukudaDepartment of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan.
Naoya FukunagaDepartment of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan.
Ryosuke TatsutaDepartment of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan.
Keiko OhnoDepartment of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Noshio, Tokyo, Japan.
Hirotaka ShibataDepartment of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan.
Hiroki ItohDepartment of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan.
Oita University · JPOita University Hospital · JPMeiji Pharmaceutical University · JP

Funding

Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (JSPS) 15K08101Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (JSPS) 19K07167
6 · The paper itself

Abstract

Response to antihypertensive drugs in patients with chronic kidney disease (CKD) has great interindividual variability. Adrenomedullin (ADM) is produced abundantly in hypertension, but clearance is very rapid. Mid-regional proADM (MR-proADM) produced from an ADM precursor is considered a surrogate biomarker for quantification of ADM. We investigated the association of MR-proADM with antihypertensive resistance in CKD patients with poor blood pressure (BP) control. This cross-sectional study analyzed 33 CKD patients with poor BP control defined as failure to achieve target BP despite at least two classes of antihypertensive drugs. Treatment intensity score was calculated to facilitate comparability of antihypertensive regimens across subjects taking different drugs. Plasma MR-proADM concentration was measured using ultra-performance liquid chromatography coupled with tandem mass spectrometry. Plasma MR-proADM concentration correlated with estimated glomerular filtration rate (eGFR) (r =  - 0.777, p < 0.001). Treatment intensity score correlated positively with plasma MR-proADM concentration (r = 0.355, p = 0.043), and the correlation was further enhanced after correction by weight (r = 0.538, p = 0.001). Single and multiple regression analysis identified MR-proADM concentration (p = 0.005) as independently associated with weight-corrected treatment intensity score. MR-proADM may be useful as a biomarker to determine the therapeutic intensity of antihypertensive drugs in CKD patients with poor BP control.

Indexed as

AdrenomedullinAntihypertensive AgentsChromatography, LiquidCross-Sectional StudiesFemaleHumansHypertensionPregnancyProtein PrecursorsRenal Insufficiency, ChronicTandem Mass SpectrometryAdrenomedullinAntihypertensive AgentsproadrenomedullinProtein Precursors

Identifiers

PMID34754024
PMCPMC8578546
OpenAlexW3214706875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.